Compare REBN & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REBN | JSPR |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 14.9M |
| IPO Year | 2017 | N/A |
| Metric | REBN | JSPR |
|---|---|---|
| Price | $1.53 | $0.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 46.8K | ★ 705.5K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,094,628.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.54 | N/A |
| 52 Week Low | $1.36 | $0.42 |
| 52 Week High | $3.40 | $7.19 |
| Indicator | REBN | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 37.53 | 34.19 |
| Support Level | $1.39 | $0.42 |
| Resistance Level | $2.00 | $1.02 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 27.50 | 25.07 |
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is a company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in two reportable segments: Reborn Coffee, which includes both the wholesale and retail sales of coffee, water, and other beverages, and Reborn Logistics, which provides freight forwarding services.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.